Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MedAdvisor is teaming up with Kings Transport to offer medication delivery to its patients
  • The contract will let MedAdvisor provide a same-day delivery service to its 3300 network pharmacies
  • The initial rollout will begin in the second half of the 2020 financial year
  • MedAdvisor’s share price is up slightly this morning with shares trading for 4.9 cents each

MedAdvisor has signed an agreement with Kings Transport to offer medication delivery to its patients.

Kings were chosen by MedAdvisor due to its national footprint, its extensive experience in the safe and appropriate delivery of medication, and its endorsement by the Pharmacy Guild of Australia.

“Kings is proud to partner with MedAdvisor to provide distribution solutions with a commitment to emerging market services and technologies,” Kings Transport CEO Barry Thompson said.

“We have had a long-standing presence within the wellness industry, so we clearly understand the strict guidelines of transporting and delivering medications,” he added.

The company says this partnership will drive the volume of orders in-app and through a pharmacy.

This agreement will allow MedAdvisor to enable same day medication delivery service to its 3300 network pharmacies.

Approximately 12 million Australian customers will have access to the service and it will include those who order directly via the app and SMS.

Over $300 million worth of medication orders passes through the MedAdvisor platform every year.

Now, access to Kings’ delivery fulfilment service will be provided seamlessly as part of each pharmacy’s PlusOne subscription and MedAdvisor will receive a share of the delivery fee.

Following technical integration, the initial rollout will begin in the second half of the 2020 financial year, focussing on major metropolitan centres.

“By adding enhanced convenience services like delivery to their customer proposition, community pharmacies can deepen the vital relationship between patients and their regular pharmacist,” MedAdvisor CEO Robert Read commented.

“Having these services activated in readiness for ePrescribing is a huge opportunity and risk mitigation for community pharmacy,” he added.

MedAdvisor’s share price is up a slight 2.08 per cent today, with shares trading for 4.9 cents apiece at 11:27 am AEDT.

MDR by the numbers
More From The Market Herald
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…